Compare OFIX & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | ATXS |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.1M | 722.1M |
| IPO Year | N/A | 2015 |
| Metric | OFIX | ATXS |
|---|---|---|
| Price | $15.51 | $12.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | $21.50 | ★ $24.33 |
| AVG Volume (30 Days) | 218.5K | ★ 1.3M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $818,058,000.00 | $706,000.00 |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.31 | N/A |
| 52 Week Low | $10.24 | $3.56 |
| 52 Week High | $20.48 | $13.29 |
| Indicator | OFIX | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 64.63 |
| Support Level | $15.51 | $12.87 |
| Resistance Level | $16.04 | $13.29 |
| Average True Range (ATR) | 0.49 | 0.22 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 44.41 | 63.68 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.